targeted treatment
Recently Published Documents


TOTAL DOCUMENTS

835
(FIVE YEARS 276)

H-INDEX

47
(FIVE YEARS 11)

2021 ◽  
Vol 19 (4) ◽  
pp. 3-5
Author(s):  
Kees Braun

Precision medicine, personalized medicine en targeted treatment: termen met een deels overlappende betekenis, allen verwijzend naar een groeiend besef in de geneeskunde: one size doesn’t fit all. Wat betekent dit voor onze epilepsiezorg?


2021 ◽  
Vol 14 (3) ◽  
pp. 379-382
Author(s):  
Adriana Morales-Moreno ◽  
José Carlos Ballena-López ◽  
Roxana Sandoval-Ahumada ◽  
Wilmer Silva-Caso ◽  
Giancarlo Pérez-Lazo

Background: Carbapenemase-producing Enterobacteriaceae (CPE) represents a global public health concern and systemic infections associated with OXA-48 carbapenemase are increasingly being reported in Latin America. Here, we present the first 2 cases of systemic infections by OXA-48-Producing Klebsiella pneumoniae in Peru. A favorable clinical response was observed after targeted treatment with colistin as a backbone.


2021 ◽  
pp. 088307382110596
Author(s):  
Hanyang Miao ◽  
Amit M. Mathur ◽  
Bhooma R. Aravamuthan

Background Early spasticity and dystonia identification in cerebral palsy is critical for guiding diagnostic workup and prompting targeted treatment early when it is most efficacious. However, differentiating spasticity from dystonia is difficult in young children with cerebral palsy. Methods We sought to determine spasticity and dystonia underidentification rates in children at high risk for cerebral palsy (following neonatal hypoxic-ischemic encephalopathy) by assessing how often child neurologists identified hypertonia alone versus specifying the hypertonia type as spasticity and/or dystonia by age 5 years. Results Of 168 children, 63 developed cerebral palsy and hypertonia but only 19 (30%) had their hypertonia type specified as spasticity and/or dystonia by age 5 years. Conclusions Child neurologists did not specify the type of hypertonia in a majority of children at high risk of cerebral palsy. Because early tone identification critically guides diagnostic workup and treatment of cerebral palsy, these results highlight an important gap in current cerebral palsy care.


2021 ◽  
Author(s):  
Iulia Peciu-Florianu ◽  
Victor Legrand ◽  
Apolline Monfilliette-Djelad ◽  
Claude-Alain Maurage ◽  
Quentin Vannod-Michel ◽  
...  

Abstract PurposeTargeted treatment for brainstem lesions requires above all a precise histopathological and molecular diagnosis. In the current technological era, robot-assisted stereotactic biopsies represent an accurate and safe procedure for tissue diagnosis. We present our center’s experience in frameless robot-assisted biopsies for brainstem lesions. MethodsWe performed a retrospective analysis of all patients benefitting from a frameless robot-guided stereotactic biopsy at our University Hospital, from 2001 to 2017. Patients consented to the use of data and/or images. The NeuroMate® robot (Renishaw™, UK) was used. We report on lesion location, trajectory strategy, histopathological diagnosis and procedure safety. ResultsOur series encompasses 96 patients (103 biopsies) treated during a 17 years period. Mean age at biopsy: 34.0 years (range 1-78). Most common location: pons (62.1%). Transcerebellar approach: 61 procedures (59.2%). Most common diagnoses: diffuse glioma (67.0%), metastases (7.8%) and lymphoma (6.8%). Non conclusive diagnosis: 10 cases (9.7%). After second biopsy this decreased to 4 cases (4.1%). Overall biopsy diagnostic yield: 95.8%. Permanent disability was recorded in 3 patients (2.9%, all adults), while transient complications in 17 patients (17.7%). Four cases of intra-tumoral hematoma were recorded (one case with rapid decline and fatal issue). Adjuvant targeted treatment was performed in 72.9% of patients. Mean follow-up (in the Neurosurgery Department): 2.2 years. ConclusionFrameless robot-assisted stereotactic biopsies can provide the initial platform towards a safe and accurate management for brainstem lesions, offering a high diagnostic yield with low permanent morbidity.


2021 ◽  
pp. 105338
Author(s):  
Maxime Samson ◽  
Hélène Greigert ◽  
André Ramon ◽  
Bernard Bonnotte

2021 ◽  
Vol Volume 14 ◽  
pp. 5507-5519
Author(s):  
Candida Vitale ◽  
Jamie Lynn Gibbons ◽  
Alessandra Ferrajoli

2021 ◽  
Vol 22 (23) ◽  
pp. 13009
Author(s):  
Xi-Dian Tang ◽  
Tian-Tian Ji ◽  
Jia-Rui Dong ◽  
Hao Feng ◽  
Feng-Qiang Chen ◽  
...  

Cytokine storm is a phenomenon characterized by strong elevated circulating cytokines that most often occur after an overreactive immune system is activated by an acute systemic infection. A variety of cells participate in cytokine storm induction and progression, with profiles of cytokines released during cytokine storm varying from disease to disease. This review focuses on pathophysiological mechanisms underlying cytokine storm induction and progression induced by pathogenic invasive infectious diseases. Strategies for targeted treatment of various types of infection-induced cytokine storms are described from both host and pathogen perspectives. In summary, current studies indicate that cytokine storm-targeted therapies can effectively alleviate tissue damage while promoting the clearance of invading pathogens. Based on this premise, “multi-omics” immune system profiling should facilitate the development of more effective therapeutic strategies to alleviate cytokine storms caused by various diseases.


Sign in / Sign up

Export Citation Format

Share Document